[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Leticia Herrero-Poch; Maria Susana Fortes-González; Antonio Pato-Pato; Pablo Gaveiras-Araújo; Martín Lorenzo-García; García-Estévez Da; Jose Ramón Lorenzo-González

doi:10.1016/j.farma.2025.12.005

February 1, 2026Farmacia HospitalariaOpen Access

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of alemtuzumab in maintaining NEDA-3 status in patients with RRMS over four years.
Annual follow-up of patients treated with alemtuzumab
Assessment of NEDA-3 parameters
Longitudinal data analysis over 4 years
Alemtuzumab showed consistent effectiveness across various NEDA-3 metrics
Sustained remission was observed in the treatment cohort
Positive outcomes in clinical practice support previous clinical trial findings

Implication

Clinical practice reports effective NEDA-3 outcomes after alemtuzumab treatment in relapsing–remitting multiple sclerosis.

Abstract

Alemtuzumab has proven to be effective, over 4 years, in clinical practice in patients with RRMS according to the different parameters of the NEDA-3 concept.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Herrero-Poch et al. (2026) studied this question.

synapsesocial.com/papers/6988270a0fc35cd7a8845ed2 https://doi.org/10.1016/j.farma.2025.12.005

View Full Paper

Ask AI

Bookmark

Share

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Implication

Abstract

Discussion

Cite This Study

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Implication

Abstract

Discussion

Cite This Study

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years